These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 27247222)

  • 1. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Sohal DP; Mangu PB; Khorana AA; Shah MA; Philip PA; O'Reilly EM; Uronis HE; Ramanathan RK; Crane CH; Engebretson A; Ruggiero JT; Copur MS; Lau M; Urba S; Laheru D
    J Clin Oncol; 2016 Aug; 34(23):2784-96. PubMed ID: 27247222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Balaban EP; Mangu PB; Khorana AA; Shah MA; Mukherjee S; Crane CH; Javle MM; Eads JR; Allen P; Ko AH; Engebretson A; Herman JM; Strickler JH; Benson AB; Urba S; Yee NS
    J Clin Oncol; 2016 Aug; 34(22):2654-68. PubMed ID: 27247216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.
    Sohal DPS; Kennedy EB; Khorana A; Copur MS; Crane CH; Garrido-Laguna I; Krishnamurthi S; Moravek C; O'Reilly EM; Philip PA; Ramanathan RK; Ruggiero JT; Shah MA; Urba S; Uronis HE; Lau MW; Laheru D
    J Clin Oncol; 2018 Aug; 36(24):2545-2556. PubMed ID: 29791286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
    Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
    BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Khorana AA; Mangu PB; Berlin J; Engebretson A; Hong TS; Maitra A; Mohile SG; Mumber M; Schulick R; Shapiro M; Urba S; Zeh HJ; Katz MH
    J Clin Oncol; 2016 Jul; 34(21):2541-56. PubMed ID: 27247221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment landscape of metastatic pancreatic cancer.
    De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
    Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for pancreatic cancer.
    Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
    Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
    Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
    Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.
    Peixoto RD; Ho M; Renouf DJ; Lim HJ; Gill S; Ruan JY; Cheung WY
    Am J Clin Oncol; 2017 Oct; 40(5):507-511. PubMed ID: 25844823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ; Chang JY; Shan YS; Chen LT
    Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.
    Garcia G; Odaimi M
    J Gastrointest Cancer; 2017 Jun; 48(2):121-128. PubMed ID: 28303435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
    Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
    Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second line treatment options for pancreatic cancer.
    Passero FC; Saif MW
    Expert Opin Pharmacother; 2017 Oct; 18(15):1607-1617. PubMed ID: 28820270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients.
    Dotan E; Catalano P; Lenchik L; Boutin R; Yao X; Marques HS; Ioffe D; Zhen DB; Li D; Wagner LI; Simon MA; Wong TZ; O'Dwyer PJ
    J Geriatr Oncol; 2023 Apr; 14(3):101474. PubMed ID: 36963200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Brus C; Saif MW
    JOP; 2010 Jul; 11(4):321-3. PubMed ID: 20601802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ductal pancreatic adenocarcinoma.
    Seufferlein T; Porzner M; Heinemann V; Tannapfel A; Stuschke M; Uhl W
    Dtsch Arztebl Int; 2014 May; 111(22):396-402. PubMed ID: 24980565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
    Cinar P; Ko AH
    Chin Clin Oncol; 2017 Jun; 6(3):29. PubMed ID: 28705006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
    Liu GF; Li GJ; Zhao H
    J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.